Navigation Links
MAP Pharmaceuticals to Present Additional Data Analyses From LEVADEX™ FREEDOM-301 Trial at 2010 European Headache and Migraine Trust International Congress
Date:10/20/2010

MOUNTAIN VIEW, Calif., Oct. 20 /PRNewswire-FirstCall/ --MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present nine analyses relating to its LEVADEX™ orally inhaled migraine therapy product candidate, including analysis from the FREEDOM-301 Phase 3 trial, at the 2010 European Headache and Migraine Trust International Congress (EHMTIC) in Nice, France.  EHMTIC is a biennial congress of the Migraine Trust and the European Headache Federation for neurologists, physicians, scientists, researchers, international experts and healthcare professionals.

An oral platform presentation titled "Utility of LEVADEX in Situations Where Early Intervention Paradigm is Impractical" reports the efficacy of LEVADEX in treating acute migraine at different time points during an attack, as early as initial migraine onset and as late as eight hours after onset of a migraine attack. It will be presented by Stewart Tepper, M.D., Director of Research for the Center for Headache and Pain at the Cleveland Clinic during the Migraine-Clinical Experiment Studies session on Sunday, October 31 at 10:40 a.m. CEST. This will also be presented as a poster (#322) starting Saturday, October 30 at 9:00 a.m. CEST.

In addition, two new analyses from the LEVADEX program will be presented in poster presentations. Poster number 460, "The Major Metabolite of Dihydroergotamine (DHE) After Oral Inhalation and IV Administration Does Not Significantly Contribute to the Pharmacological Activity," will be presented starting Thursday, October 28 at 12:00 p.m. CEST. Poster number 471, "Migraine Recurrence Rates: Case for Standardization of the Definition," will be presented starting Saturday, October 30 at 9:00 a.m. CEST.

Six additional poster presentations also will be presented in two separate sessions:

Thursday, October 28 at 12:00 p.m. CEST

  • Efficacy Evaluation of LEVADEX in Treating a Broad Spectrum of Acute Migraine Attacks (#463)
  • Evaluation of Safety and Efficacy of LEVADEX (MAP0004) in Treating Acute Menstrual Migraine (#465)
  • Evaluation of Efficacy and Safety of LEVADEX (MAP0004) in Reversing Central Sensitization and Treating Migraine in Established Allodynic Patients (#466)

  • Saturday, October 30 at 9:00 a.m. CEST

  • LEVADEX, a Novel Orally Inhaled Treatment for Acute Migraine: Efficacy and Tolerability Results of a Phase 3 Study (#462)
  • Efficacy Evaluation of LEVADEX in Treating Resistant Migraine Including Migraine with Allodynia, Morning Migraine, Disabling Migraine and Migraine Treated Late (#464)
  • The Efficacy and Tolerability of LEVADEX (Orally Inhaled DHE) for the Treatment of Migraine in Subjects with Concomitant Asthma (#467)

  • About LEVADEX™ LEVADEX orally inhaled migraine therapy is a novel migraine therapy in Phase 3 development. Patients administer LEVADEX themselves using the company's proprietary TEMPO® inhaler. LEVADEX has been designed to be differentiated from existing migraine treatments. It is a novel formulation of dihydroergotamine (DHE), a drug used intravenously in clinical settings to effectively and safely treat migraines. Based on clinical results, the company believes that LEVADEX has the potential to provide both fast onset of action, sustained pain relief and other migraine symptom relief in an easy-to-use and non-invasive at-home therapy.

    LEVADEX is designed to incorporate the multiple beneficial mechanisms of action that allow DHE to block initiation of migraine, limit pain, reduce inflammation and stop a migraine at any point in the migraine cycle. Based on research to date, including the efficacy portion of the FREEDOM-301 trial, the company believes the unique pharmacokinetic profile of LEVADEX has the potential to effectively treat migraines, while minimizing the side effects commonly seen with DHE and other currently available medicines.

    About MAP Pharmaceuticals MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The Company is developing LEVADEX inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of its Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

    Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

    Forward-Looking Statements In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' LEVADEX product candidate. Actual results may differ materially from current expectations based on risks and uncertainties affecting the Company's business, including, without limitation, risks and uncertainties relating to the conduct and completion of clinical trials, and relating to the preparation and filing of a New Drug Application and the regulatory process to have the Company's LEVADEX product candidate approved for commercial use. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2010, available at http://edgar.sec.gov. CONTACTS:Nicole FoderaroWCG(415) 946-1058    nfoderaro@wcgworld.com
    '/>"/>

    SOURCE MAP Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Alexza Pharmaceuticals Reacquires U.S. and Canadian Rights for AZ-004 (Staccato® Loxapine)
    2. Inspiration Biopharmaceuticals OBI-1 Receives Orphan Drug Designation in Europe
    3. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
    4. Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study
    5. Transcept Pharmaceuticals to Host Conference Call to Discuss Preliminary Analysis of Intermezzo® Highway Driving Study
    6. Transcept Pharmaceuticals to Present at Newsmakers in the Biotech Industry Conference
    7. Sagent Pharmaceuticals Announces Launch of ANEclear Device for Rapid Clearance of Inhaled Anesthetics Following Surgery
    8. Excaliard Pharmaceuticals Appoints Thomas Wiggans to Chairman of the Board
    9. ISTA Pharmaceuticals Receives FDA Approval for BROMDAY™
    10. Penwest Pharmaceuticals Announces Intention to Terminate NASDAQ Listing and Registration
    11. ISTA Pharmaceuticals Announces Conference Call and Webcast of Third Quarter 2010 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/7/2017)... 7, 2017  Novavax, Inc., (Nasdaq: NVAX ) ... 2 trials of its RSV F protein recombinant nanoparticle vaccine ... have been published in the journal Vaccine ... in prior scientific conferences). The Company previously announced top ... is developing the RSV F Vaccine with the goal of ...
    (Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a ... today announced new findings demonstrating positive biochemical outcomes related ... System One™. The data will be presented at the ... Madrid, Spain . The ... Home Dialysis Network in Europe ...
    (Date:5/29/2017)... -- Cellect Biotechnology Ltd. (NASDAQ: APOP ; TASE: APOP), ... selection of stem cells, today provided a corporate update ... March 31 st , 2017. "We ... quarter of 2017," said Dr. Shai Yarkoni, Chief Executive ... of the first blood cancer patient in the recently ...
    Breaking Medicine Technology:
    (Date:6/25/2017)... ... ... Month and the focus is on prostate cancer. Second only to skin cancer, prostate ... common cause of cancer related death today; lung cancer remains in the number one spot. ... during his lifetime. Those at highest risk are men who have a family ...
    (Date:6/24/2017)... ... ... Doorknobs are for convenience, deadbolts are for security. , There are many ... an alarm system installed. But unless there is a working deadbolt lock that is ... Premier Locksmith in Killeen, TX says: “In the majority of home burglaries, intruders use ...
    (Date:6/23/2017)... ... June 24, 2017 , ... Studies show evidence that carotenoids and antioxidants derived ... loss in these patients. , But how often do ophthalmologists and optometrists in Sweden ... at risk of or with early symptoms of AMD? A study published recently ...
    (Date:6/23/2017)... ... ... Goodcents Deli Fresh Subs today announced the opening of a new restaurant ... Topeka, Kan. 66604 (near 21st and Gage). It is owned and operated by long-time ... in the Topeka and Bonner Springs, Kan. area. , “Goodcents has such a ...
    (Date:6/23/2017)... ... June 23, 2017 , ... MD Now Urgent ... is MD Now’s 28th facility overall and marks the urgent care center's eighth location ... mile North of The Falls shopping mall. The new clinic offers a wide array ...
    Breaking Medicine News(10 mins):